Cargando…

Medication use by early-stage breast cancer survivors: a 1-year longitudinal study

PURPOSE: The aim of this study is to characterize the patterns of medication use by early-stage breast cancer (ESBC) survivors from diagnosis to 1 year post-chemotherapy. METHODS: A single-center longitudinal study was conducted with ESBC patients diagnosed between December 2011 and June 2014. Data...

Descripción completa

Detalles Bibliográficos
Autores principales: Loh, Kep Yong, Ng, Terence, Lee, Chee Ping, Ng, Raymond, Chan, Alexandre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4766201/
https://www.ncbi.nlm.nih.gov/pubmed/26404861
http://dx.doi.org/10.1007/s00520-015-2950-z
_version_ 1782417620089176064
author Loh, Kep Yong
Ng, Terence
Lee, Chee Ping
Ng, Raymond
Chan, Alexandre
author_facet Loh, Kep Yong
Ng, Terence
Lee, Chee Ping
Ng, Raymond
Chan, Alexandre
author_sort Loh, Kep Yong
collection PubMed
description PURPOSE: The aim of this study is to characterize the patterns of medication use by early-stage breast cancer (ESBC) survivors from diagnosis to 1 year post-chemotherapy. METHODS: A single-center longitudinal study was conducted with ESBC patients diagnosed between December 2011 and June 2014. Data on the medication use of individual patients were retrieved from prescription databases, supplemented by records from the National Electronic Health Records. The data covered the period from ESBC diagnosis to 1 year post-chemotherapy. Medication types were classified according to the World Health Organization’s Anatomical Therapeutic Chemical classification system, and medication for chronic diseases was created by adapting a list of 20 chronic diseases provided by the U.S. Department of Human and Health Services. RESULTS: Of the 107 patients involved in the study (mean age 51.1 ± 8.4 years; 78.5 % Chinese), 46.7 % manifested non-cancer comorbidities, of which hypertension (24.3 %) was the most prevalent, followed by hyperlipidemia (13.1 %) and diabetes (5.6 %). Calcium channel blockers (12.1 %) and lipid-modifying agents (11.2 %) were the most common chronic medication types used before chemotherapy, and their use persisted during chemotherapy (10.3 and 11.2 %, respectively) and after chemotherapy (11.2 and 13.1 %, respectively). Hormonal therapy was the predominant post-chemotherapy medication (77.6 %). A statistically significant increase (p < 0.0001) was observed in the mean number of chronic disease medication classes prescribed to patients between the pre-chemotherapy (0.53 ± 1.04) and chemotherapy (0.62 ± 1.08) periods and between the chemotherapy and post-chemotherapy (1.63 ± 1.35) periods. CONCLUSIONS: There is an increase in trend of chronic medication usage in breast cancer survivors after cancer treatment. This study provides important insights into the design of medication management programs tailored to this population. Future studies should incorporate a control population to improve the interpretation of study results.
format Online
Article
Text
id pubmed-4766201
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-47662012016-04-04 Medication use by early-stage breast cancer survivors: a 1-year longitudinal study Loh, Kep Yong Ng, Terence Lee, Chee Ping Ng, Raymond Chan, Alexandre Support Care Cancer Original Article PURPOSE: The aim of this study is to characterize the patterns of medication use by early-stage breast cancer (ESBC) survivors from diagnosis to 1 year post-chemotherapy. METHODS: A single-center longitudinal study was conducted with ESBC patients diagnosed between December 2011 and June 2014. Data on the medication use of individual patients were retrieved from prescription databases, supplemented by records from the National Electronic Health Records. The data covered the period from ESBC diagnosis to 1 year post-chemotherapy. Medication types were classified according to the World Health Organization’s Anatomical Therapeutic Chemical classification system, and medication for chronic diseases was created by adapting a list of 20 chronic diseases provided by the U.S. Department of Human and Health Services. RESULTS: Of the 107 patients involved in the study (mean age 51.1 ± 8.4 years; 78.5 % Chinese), 46.7 % manifested non-cancer comorbidities, of which hypertension (24.3 %) was the most prevalent, followed by hyperlipidemia (13.1 %) and diabetes (5.6 %). Calcium channel blockers (12.1 %) and lipid-modifying agents (11.2 %) were the most common chronic medication types used before chemotherapy, and their use persisted during chemotherapy (10.3 and 11.2 %, respectively) and after chemotherapy (11.2 and 13.1 %, respectively). Hormonal therapy was the predominant post-chemotherapy medication (77.6 %). A statistically significant increase (p < 0.0001) was observed in the mean number of chronic disease medication classes prescribed to patients between the pre-chemotherapy (0.53 ± 1.04) and chemotherapy (0.62 ± 1.08) periods and between the chemotherapy and post-chemotherapy (1.63 ± 1.35) periods. CONCLUSIONS: There is an increase in trend of chronic medication usage in breast cancer survivors after cancer treatment. This study provides important insights into the design of medication management programs tailored to this population. Future studies should incorporate a control population to improve the interpretation of study results. Springer Berlin Heidelberg 2015-09-25 2016 /pmc/articles/PMC4766201/ /pubmed/26404861 http://dx.doi.org/10.1007/s00520-015-2950-z Text en © The Author(s) 2015 Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Loh, Kep Yong
Ng, Terence
Lee, Chee Ping
Ng, Raymond
Chan, Alexandre
Medication use by early-stage breast cancer survivors: a 1-year longitudinal study
title Medication use by early-stage breast cancer survivors: a 1-year longitudinal study
title_full Medication use by early-stage breast cancer survivors: a 1-year longitudinal study
title_fullStr Medication use by early-stage breast cancer survivors: a 1-year longitudinal study
title_full_unstemmed Medication use by early-stage breast cancer survivors: a 1-year longitudinal study
title_short Medication use by early-stage breast cancer survivors: a 1-year longitudinal study
title_sort medication use by early-stage breast cancer survivors: a 1-year longitudinal study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4766201/
https://www.ncbi.nlm.nih.gov/pubmed/26404861
http://dx.doi.org/10.1007/s00520-015-2950-z
work_keys_str_mv AT lohkepyong medicationusebyearlystagebreastcancersurvivorsa1yearlongitudinalstudy
AT ngterence medicationusebyearlystagebreastcancersurvivorsa1yearlongitudinalstudy
AT leecheeping medicationusebyearlystagebreastcancersurvivorsa1yearlongitudinalstudy
AT ngraymond medicationusebyearlystagebreastcancersurvivorsa1yearlongitudinalstudy
AT chanalexandre medicationusebyearlystagebreastcancersurvivorsa1yearlongitudinalstudy